AstraZeneca said on Monday its vaccine for the novel coronavirus could be around 90% effective without any serious side ...

AstraZeneca reported its largest quarterly revenue ever, as soaring sales of cancer drugs helped the drugmaker beat ...

AstraZeneca (AZN.L) has informed the European Commission that it will initially not be able to deliver the agreed volumes of ...

The pharmaceutical company posted a 14% on-year increase in third-quarter core earnings per share, while revenue rose to ...

AstraZeneca CEO Pascal Soriot discusses Q3 earnings and the pharma giant's relationship with the U.S. administration.

(Reuters) -AstraZeneca shareholders approved a direct listing of the drugmaker's shares on the New York Stock Exchange on ...

Core earnings rose 12% to $2.38 per share for the three months ended September 30, topping expectations of $2.29 per share. Revenue grew 10% at constant exchange rates to $15.19 billion, also ahead of ...

AstraZeneca beat third-quarter earnings expectations on Thursday, helped by strong sales of key cancer, heart and kidney ...

AstraZeneca has seen its fair value per share revised upward from $140.96 to $144.38. This change reflects growing analyst ...

AstraZeneca said work on its new plant north of Charlottesville will begin immediately and be open within five years.

The latest investment brings the British pharma’s total investment at the site in Qingdao to $886 million. AstraZeneca ...

The decision by the Canadian regulator is supported by the findings from the Phase III DESTINY-Breast06 study.